December 19, 2017 / 1:13 PM / a month ago

BRIEF-Minerva Neurosciences Screens First Patient In Phase 3 Trial Of MIN-101 To Treat Negative Symptoms In Schizophrenia

Dec 19 (Reuters) - Minerva Neurosciences Inc:

* MINERVA NEUROSCIENCES SCREENS FIRST PATIENT IN PHASE 3 TRIAL OF MIN-101 TO TREAT NEGATIVE SYMPTOMS IN SCHIZOPHRENIA

* MINERVA NEUROSCIENCES INC - ‍ TOP-LINE RESULTS FROM 12-WEEK DOUBLE BLIND PHASE OF TRIAL OF MIN-101 ARE EXPECTED IN FIRST HALF OF 2019​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below